Use of sirolimus as an adjuvant therapy for kidney transplant recipients with high-risk cutaneous squamous cell carcinomas: a prospective non-randomized controlled study

CONCLUSIONS: This study suggests that sirolimus monotherapy may be useful as adjuvant therapy of high-risk cSCC in kidney transplant recipients. The conversion strategy used was well tolerated and safe regarding key mid-term transplant outcomes.PMID:37565728 | DOI:10.1590/2175-8239-JBN-2023-0013en

Source: Jornal Brasileiro de Nefrologia - August 11, 2023 Category: Urology & Nephrology Authors: Marina Rezende de F ázio Marina Pontello Cristelli Jane Tomimori Carlos Eiji Koga Mar ília Marufuji Ogawa Giovanni Tani Beneventi Helio Tedesco-Silva Jos é Medina-Pestana Source Type: research